MTB-9655 is under clinical development by Metabomed and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MTB-9655’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTB-9655 is under development for the treatment of advanced and metastatic solid tumors. The drug candidate is administered orally and acts by targeting acetyl-CoA short chain synthase 2 enzyme (ACSS2) .
Metabomed discovers, develops and manufactures drugs in the field of cancer metabolism and genomics. Metabomed is headquartered in Yavne, Tel Aviv, Israel.
For a complete picture of MTB-9655’s drug-specific PTSR and LoA scores, buy the report here.